BioNTech’s DB-1303 ADC Shows Promising Results in Solid Tumor Phase I/IIa Trial
Germany’s BioNTech (NASDAQ: BNTX) has released preliminary data from a Phase I/IIa trial for DB-1303,...
Gilead’s Kite Announces Breakthrough Phase III Results for Yescarta in r/r LBCL
Gilead’s (NASDAQ: GILD) subsidiary Kite has published groundbreaking Phase III results for Yescarta (axicabtagene ciloleucel),...
ITabMed Ltd Receives NMPA IND Approval for A-337, a CD3-Activating BsAb Targeting EpCAM
Shanghai-based biotech firm ITabMed Ltd has announced the receipt of Investigational New Drug (IND) approval...
China’s MOST Issues Updated HGR Rules Impacting Foreign Collaborations in Genetic Research
China’s Ministry of Science and Technology (MOST) has issued the “Detailed Implementation Rules for the...
Luye Pharma’s Lurbinectedin for Metastatic SCLC Accepted for Review by China’s NMPA
China-based Luye Pharma Group (HKG: 2186) has announced that its market filing for lurbinectedin (LY01017)...
Shanghai Runda Medical Science and Technology Partners with Huawei Cloud on AI in Healthcare
China-based Shanghai Runda Medical Science and Technology Co., Ltd (SHA: 603108) is set to collaborate...
Lee’s Pharmaceutical Subsidiary Zhaoke Ophthalmology Announces FDA Review of NVK002 for Pediatric Myopia
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has announced...
Legend Biotech Submits sBLA to Expand Carvykti Label for Relapsed Multiple Myeloma
Legend Biotech Corporation (NASDAQ: LEGN) has announced the submission of a supplemental Biologics License Application...
Zai Lab and Novocure’s TTFields Show Survival Benefit in NSCLC, Despite Stock Plunge
China-based Zai Lab Ltd (ZLAB) (NASDAQ: ZLAB; HKG: 9688) and its partner Novocure Ltd (NASDAQ:...
Shanghai Junshi Biosciences to List GDRs on Swiss Exchange, Raising RMB 3.4 Billion
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) is preparing to issue 68,292,200...
CStone Pharmaceuticals Presents Ayvakit Data for Advanced GIST at ASCO 2023
China-based CStone Pharmaceuticals (HKG: 2616) announced that new data from a post hoc analysis of...
Hansoh Pharmaceutical Gets NMPA Approval for HS-20117 Bispecific Antibody Clinical Study
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced receiving approval from the National...
Chinese Pharma Companies Update Pipelines at ASCO 2023 Annual Meeting
A number of Chinese pharmaceutical companies have shared updates on their pipeline developments at the...
Sinovac Biotech Partners with Bogota to Establish BogotáBio for Vaccine Production
China-based Sinovac Biotech Ltd (NASDAQ: SVA) has announced a strategic partnership with Bogota, the capital...
Longreach Group Puts Quasar Medical on the Block, Attracting Major Bidders
Private equity firm Longreach Group, which specializes in the Asian market, is in the process...
Gracell Biotechnologies’ GC012F Showcases Positive Data at ASCO Annual Meeting
Suzhou-based biotech firm Gracell Biotechnologies Inc., (Nasdaq: GRCL) has announced positive data for its pipeline...
Biosyngen’s BRG01 Earns Orphan Drug Designation from US FDA for Nasopharyngeal Carcinoma
Biosyngen, a leading cell therapy developer based in Guangzhou, has announced that it has received...
NMPA Clears Medtronic’s Corindus for Marketing of Advanced Coronary Surgery Systems
The National Medical Products Administration (NMPA) has granted marketing approval for the “coronary artery interventional...
NMPA Grants Market Approval for Lanzhou Kejin Taiji’s Carbon Ion Therapy System
The National Medical Products Administration (NMPA) in China has issued market approval to Lanzhou Kejin...
HighTide Therapeutics Inc. Plans Hong Kong IPO to Fund Clinical Development
China-based HighTide Therapeutics Inc. has announced plans to make an initial public offering (IPO) on...